Ascendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $153.00 by Analysts at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its price target cut by equities researchers at TD Cowen from $160.00 to $153.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s price target points to a potential upside of 20.94% from the company’s previous close.

Several other research firms also recently weighed in on ASND. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Jefferies Financial Group raised their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Citigroup increased their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Oppenheimer dropped their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Stifel Nicolaus raised their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Price Performance

ASND stock opened at $126.51 on Friday. Ascendis Pharma A/S has a 1 year low of $90.13 and a 1 year high of $161.00. The stock’s fifty day moving average price is $132.30 and its 200-day moving average price is $132.66. The company has a market cap of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, analysts expect that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its stake in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Ascendis Pharma A/S by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after acquiring an additional 4,338 shares during the period. Evolutionary Tree Capital Management LLC grew its position in shares of Ascendis Pharma A/S by 82.3% in the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock valued at $3,391,000 after purchasing an additional 11,223 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Ascendis Pharma A/S by 221.0% during the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock worth $833,000 after buying an additional 4,205 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Ascendis Pharma A/S by 1,461.1% in the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.